Presentation is loading. Please wait.

Presentation is loading. Please wait.

Low-dose Aspirin and Cancer Mortality: A Meta-analysis of Randomized Trials  Edward J. Mills, PhD, MSc, Ping Wu, MD, MSc, Mark Alberton, BSc, Steve Kanters,

Published byJulian Robertson Modified over 5 years ago

Similar presentations

Presentation on theme: "Low-dose Aspirin and Cancer Mortality: A Meta-analysis of Randomized Trials  Edward J. Mills, PhD, MSc, Ping Wu, MD, MSc, Mark Alberton, BSc, Steve Kanters,"— Presentation transcript:

1 Low-dose Aspirin and Cancer Mortality: A Meta-analysis of Randomized Trials 
Edward J. Mills, PhD, MSc, Ping Wu, MD, MSc, Mark Alberton, BSc, Steve Kanters, MSc, Angel Lanas, MD, DSc, Richard Lester, MD  The American Journal of Medicine  Volume 125, Issue 6, Pages (June 2012) DOI: /j.amjmed Copyright © 2012 Elsevier Inc. Terms and Conditions

2 Figure 1 Flow diagram of included studies. RCT = randomized clinical trial; CVD = cardiovascular disease. The American Journal of Medicine  , DOI: ( /j.amjmed ) Copyright © 2012 Elsevier Inc. Terms and Conditions

3 Figure 2 Nonvascular mortality. Forest plot displays the individual relative risk point estimates with 95% CI and the pooled overall relative risk estimate. UK-TIA = United Kingdom Transient Ischemic Attack; PHS = Physicians' Health Study; ECLAP = European Collaboration on Low-dose Aspirin in Polycythemia Vera; TPT = Thrombosis Prevention Trial; SPAF = Stroke Prevention in Atrial Fibrillation; CLIPS = Critical Leg Ischaemia Prevention Study; HOT = Hypertension Optimal Treatment; PEP = Pulmonary Embolism Prevention; FFAACS = Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontane; SALT = Swedish Aspirin Low-Dose Trial; PPP = Primary Prevention Project; POPADAD = Prevention Of Progression of Arterial Disease And Diabetes; AFASAK = The Atrial Fibrillation, Aspirin and Anticoagulant Therapy Study; SAPAT = Swedish Angina Pectoris Aspirin Trial; EAFT = European Atrial Fibrillation Trial. The American Journal of Medicine  , DOI: ( /j.amjmed ) Copyright © 2012 Elsevier Inc. Terms and Conditions

4 Figure 3 Cancer mortality. Forest plot shows the individual relative risk point estimates with 95% CI and the pooled overall relative risk estimate. UK-TIA = United Kingdom Transient Ischemic Attack; TPT = Thrombosis Prevention Trial; CLIPS = Critical Leg Ischaemia Prevention Study; FFAACS = Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontane; SALT = Swedish Aspirin Low-Dose Trial; POPADAD = Prevention Of Progression of Arterial Disease And Diabetes; SAPAT = Swedish Angina Pectoris Aspirin Trial. The American Journal of Medicine  , DOI: ( /j.amjmed ) Copyright © 2012 Elsevier Inc. Terms and Conditions

5 Figure 4 Cumulative effects of aspirin on cancer mortality. Cumulative Forest plot shows the individual relative risk point estimates with 95% CI according to shortest to longest duration of trials reporting cancer mortality. FFAACS = Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontane; CLIPS = Critical Leg Ischaemia Prevention Study; SALT = Swedish Aspirin Low-Dose Trial; TPT = Thrombosis Prevention Trial; UK-TIA = United Kingdom Transient Ischemic Attack; SAPAT = Swedish Angina Pectoris Aspirin Trial; POPADAD = Prevention Of Progression of Arterial Disease And Diabetes. The American Journal of Medicine  , DOI: ( /j.amjmed ) Copyright © 2012 Elsevier Inc. Terms and Conditions

Download ppt "Low-dose Aspirin and Cancer Mortality: A Meta-analysis of Randomized Trials  Edward J. Mills, PhD, MSc, Ping Wu, MD, MSc, Mark Alberton, BSc, Steve Kanters,"

Similar presentations

Low-Dose Aspirin in Patients with Stable Cardiovascular Disease: A Meta-analysis Jeffrey S. Berger, MD, MS, David L. Brown, MD, Richard C. Becker, MD The.

Low-Dose Aspirin in Patients with Stable Cardiovascular Disease: A Meta-analysis Jeffrey S. Berger, MD, MS, David L. Brown, MD, Richard C. Becker, MD The.
Date of download: 6/21/2016 From: Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services.

Date of download: 6/21/2016 From: Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Aspirin Therapy in Primary Cardiovascular Disease.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Aspirin Therapy in Primary Cardiovascular Disease.
Date of download: 6/26/2016 From: Aspirin for the Prevention of Cancer Incidence and Mortality: Systematic Evidence Reviews for the U.S. Preventive Services.

Date of download: 6/26/2016 From: Aspirin for the Prevention of Cancer Incidence and Mortality: Systematic Evidence Reviews for the U.S. Preventive Services.
Date of download: 7/10/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Choice of Antithrombotic Therapy for Stroke Prevention.

Date of download: 7/10/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Choice of Antithrombotic Therapy for Stroke Prevention.
Volume 370, Issue 9586, Pages (August 2007)

Volume 370, Issue 9586, Pages (August 2007)
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis  Stavros Stavrakis, MD  The American Journal.

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis  Stavros Stavrakis, MD  The American Journal.
Overweight and obesity as risk factors for atrial fibrillation or flutter: The Danish Diet, Cancer, and Health Study  Lars Frost, MD, PhD, Lone Juul Hune,

Overweight and obesity as risk factors for atrial fibrillation or flutter: The Danish Diet, Cancer, and Health Study  Lars Frost, MD, PhD, Lone Juul Hune,
From: Adjusted-Dose Warfarin versus Aspirin for Preventing Stroke in Patients with Atrial Fibrillation Ann Intern Med. 2007;147(8):590-592. doi:10.7326/0003-4819-147-8-200710160-00018.

From: Adjusted-Dose Warfarin versus Aspirin for Preventing Stroke in Patients with Atrial Fibrillation Ann Intern Med. 2007;147(8): doi: /
Paul D. Stein, MD, Fadi Matta, MD, Mary J. Hughes, DO 

Paul D. Stein, MD, Fadi Matta, MD, Mary J. Hughes, DO 
New-onset Atrial Fibrillation Predicts Heart Failure Progression

New-onset Atrial Fibrillation Predicts Heart Failure Progression
Aspirin Use Among U.S. Adults

Aspirin Use Among U.S. Adults
Alfred A. Bartolucci, PhD, Michal Tendera, MD, George Howard, DrPH 

Alfred A. Bartolucci, PhD, Michal Tendera, MD, George Howard, DrPH 
Long-term Low-Molecular-Weight Heparin versus Usual Care in Proximal-Vein Thrombosis Patients with Cancer  Russell D. Hull, MBBS, MSc, Graham F. Pineo,

Long-term Low-Molecular-Weight Heparin versus Usual Care in Proximal-Vein Thrombosis Patients with Cancer  Russell D. Hull, MBBS, MSc, Graham F. Pineo,
Role of the CHADS2 Score in Acute Coronary Syndromes

Role of the CHADS2 Score in Acute Coronary Syndromes
Renato D. Lopes, MD, PhD, Li Li, MS, Christopher B

Renato D. Lopes, MD, PhD, Li Li, MS, Christopher B
Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study  Torben Bjerregaard Larsen, MD,

Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study  Torben Bjerregaard Larsen, MD,
Alternative Smoking Cessation Aids: A Meta-analysis of Randomized Controlled Trials  Mehdi Tahiri, MD, Salvatore Mottillo, MD, Lawrence Joseph, PhD, Louise.

Alternative Smoking Cessation Aids: A Meta-analysis of Randomized Controlled Trials  Mehdi Tahiri, MD, Salvatore Mottillo, MD, Lawrence Joseph, PhD, Louise.
Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention  Chirag Bavishi, MD, MPH,

Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention  Chirag Bavishi, MD, MPH,
Impact of More Restrictive Blood Transfusion Strategies on Clinical Outcomes: A Meta- analysis and Systematic Review  Shelley R. Salpeter, MD, Jacob S.

Impact of More Restrictive Blood Transfusion Strategies on Clinical Outcomes: A Meta- analysis and Systematic Review  Shelley R. Salpeter, MD, Jacob S.

Similar presentations

Ads by Google